企業プロフィール
10x Genomics 株価・ニュース・カタリスト
- ティッカー:
- TXG
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
88.76 USD (-1.77%)
終値
最終更新: 2026年10月1日
3.9B USD
時価総額
株価変動の要因
2026年10月1日 時点で TXG は 1.77% 下落し、$88.76 で取引を終えました。現在のニュース監視期間内に同社の新しいニュースは確認されませんでした。
企業概要
Single-Cell and Spatial Biology Company
10x Genomics develops instruments, consumables, software, and analysis tools that allow researchers to measure biological systems at single-cell and spatial resolution. Its platforms are used across academic research, translational medicine, biopharma discovery, and emerging diagnostic applications.
Chromium Single-Cell Platform
The Chromium platform partitions cells and biological molecules for high-throughput analysis of gene expression, immune repertoires, chromatin accessibility, and multiomic features. Instrument placements support recurring sales of proprietary chips, reagents, and workflow consumables.
Visium Spatial Profiling
Visium products measure gene expression while preserving tissue location, allowing researchers to connect molecular signals with histology and tissue architecture. The platform supports discovery across oncology, neuroscience, immunology, developmental biology, and pathology research.
Xenium In Situ Analysis
Xenium performs targeted, high-plex RNA analysis directly within tissue sections at subcellular resolution. It complements Visium by enabling researchers to study selected gene panels with detailed spatial localization and cell-level morphology.
Next-Generation Platforms and Software
Atera is designed to expand the scale and flexibility of spatial biology, while the acquisition of Proteintech Genomics adds antibody-based protein measurement capabilities. 10x Genomics is also investing in software and computational tools that convert large single-cell and spatial datasets into interpretable biological conclusions.
今後のカタリスト
- Global commercial shipments of the Atera spatial biology platform in the second half of 2026.
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。